Is The Bad News Priced Into Nike Stock Now?
Despite its dominance in the athletic shoe and apparel industry,…
Sell
25
AARD Quote, Financials, Valuation and Earnings
Last price:
$8.69
Seasonality move
:
--
Day range:
$8.34 - $9.19
52-week range:
$6.79 - $19.58
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
149.3K
Avg. volume:
131.2K
1-year change:
--
Market cap:
$187M
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AARD
Aardvark Therapeutics
|
-- | -$0.67 | -- | -261.35% | $32.33 |
|
BMEA
Biomea Fusion
|
-- | -$0.60 | -- | -46.94% | $22.78 |
|
GEHC
GE HealthCare Technologies
|
$4.7B | $0.91 | 0.19% | 12.73% | $100.16 |
|
ITCI
Intra-Cellular Therapies
|
$205.6M | -$0.10 | 41.9% | -21.88% | $132.00 |
|
PLRX
Pliant Therapeutics
|
-- | -$0.75 | 61.11% | -1.32% | $10.06 |
|
SLNO
Soleno Therapeutics
|
-- | -- | -- | -- | $102.13 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AARD
Aardvark Therapeutics
|
$8.62 | $32.33 | $187M | -- | $0.00 | 0% | -- |
|
BMEA
Biomea Fusion
|
$1.95 | $22.78 | $73.3M | -- | $0.00 | 0% | -- |
|
GEHC
GE HealthCare Technologies
|
$72.00 | $100.16 | $32.9B | 16.63x | $0.04 | 0.17% | 1.68x |
|
ITCI
Intra-Cellular Therapies
|
$131.87 | $132.00 | $14B | -- | $0.00 | 0% | 19.98x |
|
PLRX
Pliant Therapeutics
|
$1.41 | $10.06 | $86.3M | -- | $0.00 | 0% | 16.98x |
|
SLNO
Soleno Therapeutics
|
$73.67 | $102.13 | $3.4B | -- | $0.00 | 0% | 3,781.41x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AARD
Aardvark Therapeutics
|
-- | 0.000 | -- | -- |
|
BMEA
Biomea Fusion
|
-- | 2.580 | -- | -- |
|
GEHC
GE HealthCare Technologies
|
51.45% | 1.336 | 24.91% | 0.76x |
|
ITCI
Intra-Cellular Therapies
|
-- | 0.214 | -- | 5.68x |
|
PLRX
Pliant Therapeutics
|
-- | 3.584 | -- | -- |
|
SLNO
Soleno Therapeutics
|
-- | -2.069 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AARD
Aardvark Therapeutics
|
-- | -- | -- | -- | -- | -- |
|
BMEA
Biomea Fusion
|
-- | -$34M | -- | -- | -- | -$25.4M |
|
GEHC
GE HealthCare Technologies
|
$2.3B | $801M | 11.43% | 24.88% | 17.77% | $811M |
|
ITCI
Intra-Cellular Therapies
|
$178.8M | -$29.2M | -8.07% | -8.07% | -14.66% | -$12.7M |
|
PLRX
Pliant Therapeutics
|
-- | -$53.3M | -- | -- | -- | -$47.9M |
|
SLNO
Soleno Therapeutics
|
-- | -$58.8M | -- | -- | -- | -$24M |
Aardvark Therapeutics vs. Competitors
-
Which has Higher Returns AARD or BMEA?
Biomea Fusion has a net margin of -- compared to Aardvark Therapeutics's net margin of --. Aardvark Therapeutics's return on equity of -- beat Biomea Fusion's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AARDAardvark Therapeutics-- -- -- BMEABiomea Fusion-- -$0.91 -- -
What do Analysts Say About AARD or BMEA?
Aardvark Therapeutics has a consensus price target of $32.33, signalling upside risk potential of 265.43%. On the other hand Biomea Fusion has an analysts' consensus of $22.78 which suggests that it could grow by 1068.09%. Given that Biomea Fusion has higher upside potential than Aardvark Therapeutics, analysts believe Biomea Fusion is more attractive than Aardvark Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings AARDAardvark Therapeutics2 0 0 BMEABiomea Fusion4 2 0 -
Is AARD or BMEA More Risky?
Aardvark Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Biomea Fusion has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock AARD or BMEA?
Aardvark Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomea Fusion offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aardvark Therapeutics pays -- of its earnings as a dividend. Biomea Fusion pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AARD or BMEA?
Aardvark Therapeutics quarterly revenues are --, which are smaller than Biomea Fusion quarterly revenues of --. Aardvark Therapeutics's net income of -- is lower than Biomea Fusion's net income of -$32.8M. Notably, Aardvark Therapeutics's price-to-earnings ratio is -- while Biomea Fusion's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aardvark Therapeutics is -- versus -- for Biomea Fusion. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AARDAardvark Therapeutics-- -- -- -- BMEABiomea Fusion-- -- -- -$32.8M
-
Which has Higher Returns AARD or GEHC?
GE HealthCare Technologies has a net margin of -- compared to Aardvark Therapeutics's net margin of 13.56%. Aardvark Therapeutics's return on equity of -- beat GE HealthCare Technologies's return on equity of 24.88%.
Company Gross Margin Earnings Per Share Invested Capital AARDAardvark Therapeutics-- -- -- GEHCGE HealthCare Technologies42.77% $1.57 $17.6B -
What do Analysts Say About AARD or GEHC?
Aardvark Therapeutics has a consensus price target of $32.33, signalling upside risk potential of 265.43%. On the other hand GE HealthCare Technologies has an analysts' consensus of $100.16 which suggests that it could grow by 39.1%. Given that Aardvark Therapeutics has higher upside potential than GE HealthCare Technologies, analysts believe Aardvark Therapeutics is more attractive than GE HealthCare Technologies.
Company Buy Ratings Hold Ratings Sell Ratings AARDAardvark Therapeutics2 0 0 GEHCGE HealthCare Technologies12 4 1 -
Is AARD or GEHC More Risky?
Aardvark Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison GE HealthCare Technologies has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock AARD or GEHC?
Aardvark Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GE HealthCare Technologies offers a yield of 0.17% to investors and pays a quarterly dividend of $0.04 per share. Aardvark Therapeutics pays -- of its earnings as a dividend. GE HealthCare Technologies pays out 2.76% of its earnings as a dividend. GE HealthCare Technologies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AARD or GEHC?
Aardvark Therapeutics quarterly revenues are --, which are smaller than GE HealthCare Technologies quarterly revenues of $5.3B. Aardvark Therapeutics's net income of -- is lower than GE HealthCare Technologies's net income of $721M. Notably, Aardvark Therapeutics's price-to-earnings ratio is -- while GE HealthCare Technologies's PE ratio is 16.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aardvark Therapeutics is -- versus 1.68x for GE HealthCare Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AARDAardvark Therapeutics-- -- -- -- GEHCGE HealthCare Technologies1.68x 16.63x $5.3B $721M
-
Which has Higher Returns AARD or ITCI?
Intra-Cellular Therapies has a net margin of -- compared to Aardvark Therapeutics's net margin of -8.48%. Aardvark Therapeutics's return on equity of -- beat Intra-Cellular Therapies's return on equity of -8.07%.
Company Gross Margin Earnings Per Share Invested Capital AARDAardvark Therapeutics-- -- -- ITCIIntra-Cellular Therapies89.76% -$0.16 $1.1B -
What do Analysts Say About AARD or ITCI?
Aardvark Therapeutics has a consensus price target of $32.33, signalling upside risk potential of 265.43%. On the other hand Intra-Cellular Therapies has an analysts' consensus of $132.00 which suggests that it could grow by 0.1%. Given that Aardvark Therapeutics has higher upside potential than Intra-Cellular Therapies, analysts believe Aardvark Therapeutics is more attractive than Intra-Cellular Therapies.
Company Buy Ratings Hold Ratings Sell Ratings AARDAardvark Therapeutics2 0 0 ITCIIntra-Cellular Therapies1 5 0 -
Is AARD or ITCI More Risky?
Aardvark Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Intra-Cellular Therapies has a beta of 0.462, suggesting its less volatile than the S&P 500 by 53.815%.
-
Which is a Better Dividend Stock AARD or ITCI?
Aardvark Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intra-Cellular Therapies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aardvark Therapeutics pays -- of its earnings as a dividend. Intra-Cellular Therapies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AARD or ITCI?
Aardvark Therapeutics quarterly revenues are --, which are smaller than Intra-Cellular Therapies quarterly revenues of $199.2M. Aardvark Therapeutics's net income of -- is lower than Intra-Cellular Therapies's net income of -$16.9M. Notably, Aardvark Therapeutics's price-to-earnings ratio is -- while Intra-Cellular Therapies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aardvark Therapeutics is -- versus 19.98x for Intra-Cellular Therapies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AARDAardvark Therapeutics-- -- -- -- ITCIIntra-Cellular Therapies19.98x -- $199.2M -$16.9M
-
Which has Higher Returns AARD or PLRX?
Pliant Therapeutics has a net margin of -- compared to Aardvark Therapeutics's net margin of --. Aardvark Therapeutics's return on equity of -- beat Pliant Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AARDAardvark Therapeutics-- -- -- PLRXPliant Therapeutics-- -$0.82 -- -
What do Analysts Say About AARD or PLRX?
Aardvark Therapeutics has a consensus price target of $32.33, signalling upside risk potential of 265.43%. On the other hand Pliant Therapeutics has an analysts' consensus of $10.06 which suggests that it could grow by 613.65%. Given that Pliant Therapeutics has higher upside potential than Aardvark Therapeutics, analysts believe Pliant Therapeutics is more attractive than Aardvark Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings AARDAardvark Therapeutics2 0 0 PLRXPliant Therapeutics1 11 0 -
Is AARD or PLRX More Risky?
Aardvark Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pliant Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock AARD or PLRX?
Aardvark Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pliant Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aardvark Therapeutics pays -- of its earnings as a dividend. Pliant Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AARD or PLRX?
Aardvark Therapeutics quarterly revenues are --, which are smaller than Pliant Therapeutics quarterly revenues of --. Aardvark Therapeutics's net income of -- is lower than Pliant Therapeutics's net income of -$49.7M. Notably, Aardvark Therapeutics's price-to-earnings ratio is -- while Pliant Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aardvark Therapeutics is -- versus 16.98x for Pliant Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AARDAardvark Therapeutics-- -- -- -- PLRXPliant Therapeutics16.98x -- -- -$49.7M
-
Which has Higher Returns AARD or SLNO?
Soleno Therapeutics has a net margin of -- compared to Aardvark Therapeutics's net margin of --. Aardvark Therapeutics's return on equity of -- beat Soleno Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AARDAardvark Therapeutics-- -- -- SLNOSoleno Therapeutics-- -$1.27 -- -
What do Analysts Say About AARD or SLNO?
Aardvark Therapeutics has a consensus price target of $32.33, signalling upside risk potential of 265.43%. On the other hand Soleno Therapeutics has an analysts' consensus of $102.13 which suggests that it could grow by 38.63%. Given that Aardvark Therapeutics has higher upside potential than Soleno Therapeutics, analysts believe Aardvark Therapeutics is more attractive than Soleno Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings AARDAardvark Therapeutics2 0 0 SLNOSoleno Therapeutics5 0 0 -
Is AARD or SLNO More Risky?
Aardvark Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Soleno Therapeutics has a beta of -2.285, suggesting its less volatile than the S&P 500 by 328.466%.
-
Which is a Better Dividend Stock AARD or SLNO?
Aardvark Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Soleno Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aardvark Therapeutics pays -- of its earnings as a dividend. Soleno Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AARD or SLNO?
Aardvark Therapeutics quarterly revenues are --, which are smaller than Soleno Therapeutics quarterly revenues of --. Aardvark Therapeutics's net income of -- is lower than Soleno Therapeutics's net income of -$56M. Notably, Aardvark Therapeutics's price-to-earnings ratio is -- while Soleno Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aardvark Therapeutics is -- versus 3,781.41x for Soleno Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AARDAardvark Therapeutics-- -- -- -- SLNOSoleno Therapeutics3,781.41x -- -- -$56M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is LUV Stock a Buy, Sell or Hold?
Southwest Airlines (NYSE:LUV) is one of America’s major air transportation…
Should I Buy Alcoa Stock?
Alcoa (AA) finds itself in an interesting position in early…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 33x
Sell
43
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
37
Is NVDA Stock a Buy?
Market Cap: $2.5T
P/E Ratio: 35x
Alerts
Sell
24
DPST alert for Apr 4
Direxion Daily Regional Banks Bull 3X Shares [DPST] is down 31.13% over the past day.
Sell
9
FIVE alert for Apr 4
Five Below [FIVE] is down 27.86% over the past day.
Sell
10
COHR alert for Apr 4
Coherent [COHR] is down 20.24% over the past day.
